Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Kioxia shares rise as much as 5.8% after reports that it plans to build a new chipmaking plant in northern Japan, as chipmaker Nvidia identified memory hardware shortages as a key issue in their earnings report.
- Z.AI shares jumped as much as 8.6% after the Chinese AI company confirmed it’s responsible for the Ox Alpha AI model that swept to the top of online usage charts this weekend.
- Hainan Jinpan shares tumble alongside other Chinese energy stocks after President Donald Trump moved to restrict some foreign-made transformers and other critical energy equipment from US grids on national security grounds.
See omnystudio.com/listener for privacy information.

Today’s biggest winners and losers in the stock market.
On this episode of Stock Movers:
Shares of Nvidia (NVDA) soared in late trading after the chipmaker at the heart of the artificial intelligence boom gave a bullish sales outlook for 2028, easing concerns that an AI spending surge is losing momentum. “We expect to grow revenue by approximately 70% in fiscal 2028,” Chief Financial Officer Colette Kress said during a post-earnings conference call. Analysts have projected a rise of about 45% for that year, according to data compiled by Bloomberg. Moreover, Nvidia would be growing even faster if it had access to more supplies, she said. “Incredibly, we are seeing demand acceleration even at our scale,” she said. “Customers’ forecasts point to our growth doubling next year.”
Shares of Crowdstrike (CRWD) rose Wednesday on a strong financial report that saw it forecast revenue figures for the full year that exceeded analysts’ estimates, evidence that the cybersecurity industry continues to see demand driven by threats from artificial intelligence. Revenue for the third quarter will be as high as $1.53 billion, the Austin-based security software firm said in a statement Wednesday. Analysts, on average, estimated $1.52 billion, according to estimates compiled by Bloomberg. The company forecast annual revenue of $5.99 billion to $6.01 billion, ahead of estimates of $5.94 billion.
Shares of Salesforce (CRM) soared in extended trading, after the software company gave an outlook for strong revenue expansion and deepened its partnership with Anthropic PBC, reassuring investors that it can compete successfully in the AI era. Sales will be about $11.5 billion in the fiscal third quarter, which ends in October, Salesforce said Wednesday in a statement. That’s just ahead of analysts’ average estimates, according to data compiled by Bloomberg. Current remaining performance obligations — a measure of future sales — will increase about 14%, also ahead of the average estimate of 13% growth.
See omnystudio.com/listener for privacy information.

Today’s biggest winners and losers in the stock market.
On this episode of Stock Movers:
Shares of Meta Platforms (META) gained ahead of the Wednesday close after the social media giant said it agreed to pay up to $18 billion in landmark settlements to resolve legal claims from US states that would require the company to make major changes to how it operates platforms like Facebook and Instagram. Key parts of the deal, disclosed in a court filing Wednesday, require the company to put new guardrails on its platforms, including restricting how much time youths can scroll and preventing them from switching off certain safety settings without parental consent.
Shares of Nvidia (NVDA) moved lower ahead of the company’s latest earnings report. Investors are eagerly awaiting Nvidia’s numbers for clues on what they mean to the artificial-intelligence trade and the market itself. Analysts project that revenue nearly doubled from a year ago, which would be the fastest pace in two years, according to data compiled by Bloomberg.
Shares of Revolution Medicines Inc. (RVMD) gained in the Wednesday session after the FDA approved the firm’s once-daily tablet for adults with metastatic pancreatic cancer, the first medicine to target one of the key molecular causes of the disease. The drug, which will be called Rasonque, is one of the more significant breakthroughs in pancreatic cancer in years. In a final stage trial published in May, daraxonrasib nearly doubled typical survival time for patients with an aggressive form of the disease to 13.2 months, compared with 6.7 months for patients who received chemotherapy, the current standard of care, according to the US Food and Drug Administration.
See omnystudio.com/listener for privacy information.

Abercrombie & Fitch (ANF) shares soar. Abercrombie & Fitch shares jump as much as 30% to trade at their highest intraday level since January 2025 after the apparel retailer raised its adjusted earnings per share guidance for the full year.
-J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%.
-Zoom Communications (ZM) shares fall. The software company’s second-quarter results were seen as mixed. It also gave outlooks for adjusted third-quarter earnings and operating income that were weaker than expected.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
-Nvidia (NVDA) drops ahead of quarterly earnings. Wall Street is anticipating Nvidia Corp.'s earnings for what they mean to artificial intelligence investors and the market itself. Nvidia is considered the best barometer for AI spending, and its earnings will help determine if hyperscalers are still accelerating or becoming more disciplined.
-Intuit (INTU) shares slump. The tax-preparation software company gave a full-year forecast for both adjusted earnings and revenue that was weaker than expected, and which added to concerns about AI-related disruption.
- J M Smucker (SJM) raised its full-year outlook for sales and profit, buoyed by growth in its Uncrustables sandwiches and coffee. The packaged food company said it now expects adjusted earnings per share for fiscal 2027 of between $10.50 and $11.00, up from its prior estimate of $9.75 to $10.25. Smucker expects net sales to fall 1% to 2%, an improvement over its previous forecast of a decline of 3% to 4%.
See omnystudio.com/listener for privacy information.